

214

ORAL

FOTEMUSTINE, DACARBAZINE (DTIC) AND INTERFERON α -2A (IFN) TREATMENT OF METASTATIC MELANOMA. PRELIMINARY DATA

P. Comella¹, F. Presutti², A. Daponte¹, R. Casaretti, G. Frasci, G. Palmieri¹, R. Gargiulo¹, M. Annunziata¹, A. Balasco, J. Perchard, G. Comella¹

¹Division of Medical Oncology A, National Tumor Institute, Naples, Italy

²Servier Research Institute, Roma, Italy

Purpose: This phase II study was undertaken to define the toxicity and therapeutic activity of a Fotemustine-DTIC-IFN combination in patients (pts) with metastatic melanoma.

Methods: Treatment consisted of Fotemustine 100 mg/m² i.v. d 1, DTIC 250 mg/m² d 2-5 every 3 weeks. IFN 3 MUI was administered i.m. 3 times a week throughout the chemotherapy administration.

Results: At the time of this analysis (08-03-1995) 35 pts (20 M, 15 F; age range 24-75 years; 26 chemotherapy-naïve; 26 with visceral or SNC involvement) have been treated for a total of 125 courses. Twenty-six pts are presently evaluable for response (3 non-eligible for major protocol violation, and 6 too early). One CR and 5 PR have been observed for a 23% ORR [95% C.I.: 9-44]. The patient with CR had skin, lymph nodal and renal involvement at beginning of the treatment.

Toxicity: 32 pts are evaluable for toxicity for a total of 122 courses. The treatment has been generally well tolerated. Toxic deaths have not been registered. Leucopenia and thrombocytopenia of grade 3-4 have been observed in only 2.5% and 6.5% of the total delivered courses respectively. Grade 3 anemia occurred in one patient. IFN-related fever occurred in 11.5% of the courses and was always mild.

Conclusions: Fotemustine-DTIC-IFN combination seems a well tolerated and quite effective treatment for patients with metastatic melanoma. Since we chose a 35% ORR as target activity level, and considered 20% ORR as the lowest level of interest, at least 7 responses in 31 evaluable pts are required in the first-stage of the trial to continue the accrual to a total of 53 pts.

215

ORAL

DACARBAZINE-VINDESINE VS DACARBAZINE-VINDESINE-CISPLATINUM IN DISSEMINATED MELANOMA—A RANDOMIZED PHASE III TRIAL

U. Jørgensen, U. Ringborg, S. Aamdahl, C.-M. Rudenstam, U. Stierner, C. Ingvar, P. Malmström, R. Andersson, M. Karlsson, K. Willman, E. Wist, R. Westberg

Clinic of Oncology, Radiumhemmet, Karolinska Hospital, S-171 76 Stockholm, Sweden

In a phase III study of disseminated malignant melanoma performed in Sweden and Norway, 326 patients were randomized to receive treatment with the combination Dacarbazine (DTIC) and Vindesine (VDS) with or without addition of Cisplatin (CDDP). The study was designed to reveal a clinically significant survival difference when the three drugs were combined. DTIC was given i.v. at a dose of 250 mg/sqm days 1 to 5 every four weeks and VDS was given i.v. at a dose of 3.0 mg/sqm day 1 weekly. CDDP was given i.v. at a dose of 100 mg/sqm day 1 every 4 weeks. There was no statistical significant difference regarding total survival between the treatment arms ($P = 0.22$). What was clearly demonstrated was an increased toxicity in the treatment arm containing CDDP. Two hundred and sixteen patients were evaluable for response in compliance with the WHO criteria. With the DTIC-VDS regimen 9.9% patients obtained a complete remission and 10.8% patients a partial remission with an overall response rate of 20.7%. With the triple regimen DTIC-VDS-CDDP 16.2% patients obtained a complete remission and 15.2% patients a partial remission with an overall response of 31.4%. The difference in objective response rates observed between the treatment arms is not statistically significant ($P = 0.1011$). In conclusion this study did not show any significant increases in median survival time or objective response rate. The study has demonstrated a clinically significant increase in toxicity and we suggest that this triple regimen does not merit further use in patients with disseminated malignant melanoma, which earlier phase II studies have indicated.

216

ORAL

ISOLATED LIMB PERFUSION FOR STAGE IIIA-IIIAB MELANOMA: TNF + L-PAM AND L-PAM + HYPERTHERMIA *M. Santinami, M. Deraco, M.G. Inglese, R. Manzi, L. Persiani, N. Santoro, C. Sequeira, M. Vaglini, N. Cascinelli* *National Cancer Institute, 20133 Milan, Italy*

The aim of this report is to compare two different approaches using ILP. Two series of patients with stage IIIA or IIIAB melanoma were treated by ILP at the National Cancer Institute, Milan. Forty-four patients (group 1) received α -tumor necrosis factor (α -TNF; 1-4 mg) plus melphalan (50-100 mg) and mild hyperthermia (39°C), while 133 patients (group 2) were treated using melphalan (50-100 mg) and hyperthermia (40.5°-41°). No significant differences were obtained in terms of both overall response rate (complete plus partial responses) in the two series of patients (70.4% in group 1; 87.2% in group 2) and relapse rate (34.1% in group 1; 44.4% in group 2). A significant difference in the appearance of new relapses was observed (6 months for group 1; 13 months for group 2). After a median follow-up of 11 months in group 1, 52.3% of patients have no evidence of disease, and 31.8% are alive with disease. In group 2 after a mean follow-up of 43 months, 30% of patients have no evidence of disease, and 8.3% are alive with disease. In conclusion, our experience did not confirm the impressive results demonstrated by other authors using α -TNF by ILP.

This work has been supported by AIRC, contribution 1994.

217

ORAL

THE EUROPEAN EXPERIENCE IN TNF α ISOLATED LIMB PERFUSIONS FOR NONRESECTABLE EXTREMITY SOFT TISSUE SARCOMAS: 85% RESPONSE RATE; 87% LIMB SALVAGE

A.M.M. Eggermont¹, H. Schraffordt Koops², B.B.R. Kroon³, J.M. Klausner⁴, P.M. Schlag⁵, F.J. Lejeune⁶

¹Rotterdam Cancer Institute, Netherlands, ²University Hospital, Groningen, Netherlands, ³Netherlands Cancer Institute, Netherlands, ⁴Ichilov Hospital, Tel Aviv, Israel, ⁵Max Delbrück Cancer Center, Berlin, Germany, and ⁶C.P.O. Lausanne, Switzerland.

Goal: Achieve limb salvage in patients with irresectable soft tissue sarcoma (STS) of an extremity by ILP with TNF α \pm IFN-gamma and Melphalan.

Material and Methods: 120 patients (pts) with nonresectable STS of the extremities were treated without IFN (65) or with 0.2 mg IFN (55) s.c. on the 2 days prior to a 90 minutes ILP with 0.2 mg IFN, 4 mg TNF (leg) or 3 mg TNF (arm), and 10 mg/L (leg)—13 mg/L (arm) limb volume of Melphalan at 39-40 °C. In 20% of the patients there were multiple sarcomas in the extremities. Residual tumors were resected (after 2-6 months) after maximal shrinkage (often 90%-100% necrotic). TNF α /IFN Boehringer Ingelheim GmbH.

Results: In 55 patients treated with TNF + IFN + Melphalan: 20 CR (36.4%), 29 PR (52.7%), 6 SD (11%); in 65 patients treated with TNF + Melphalan: 20 CR (30.8%), 33 PR (50.8%), 12 NC (18.4%). Median follow up of first 55 pts 18 + months (9 + -40 + months). Most tumors became resectable 2-3 months after ILP. Limb salvage rate was 49/55 (87.3%) and 56/65 (86%). Toxicity was moderate (grade I-II) and transient grade III liver toxicity. There were no toxic deaths.

Conclusion: Isolated limb perfusion with TNF α , \pm IFN-gamma and Melphalan is safe and very effective against locally advanced extremity soft tissue sarcomas.

218

ORAL

DERMATOFIBROSARCOMA PROTUBERANS: CONTROL BY RADIATION

H.D. Suit, I.J. Spiro, K. Tanabe

Departments of Radiation Oncology and Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, U.S.A.

Dermatofibrosarcoma protuberans is an exceptionally low grade malignant fibroblastic neoplasm of the dermis. Metastasis are almost unknown following successful treatment of the primary lesion. Histopathologically, DFSP closely resembles benign fibrous histiocytoma. These lesions locally infiltrate and exhibit a high local regrowth rate following conservative surgery. We have employed radiation in the management of 16 patients for their DFSP alone or in combination with surgery. No patient has been lost to follow-up with the most recent examination at 2 to 10 years post treatment. The tumors were primary (11) and recurrent (5). Local control has been achieved in 14 of the 16; 9 of 11 primary and 5 of 5 recurrent DFSP. Treatment has been radiation and

surgery in 12 with local control in 10 of 12. The 4 patients treated by radiation alone have local control (4/4); 3 of these were recurrent following prior surgery. The two patients who failed locally after surgery and post-operative radiation are alive without evidence of their DFSP at >2 years following salvage surgery.

This limited experience demonstrates that radiation is an effective therapeutic modality against DFSP and can be recommended for those patients who are inoperable for medical or technical reasons or for whom the functional cosmetic price would be unacceptable to the patient.

219

POSTER

SECOND PRIMARY TUMOURS IN MELANOMA PATIENTS

A. Bellacci, S. Mori, S. Nesi, A. Galli, M. Pace

Institute of General Surgical Clinic, University of Florence, Florence, Italy

Many authors report a high incidence of second primary tumours in patients affected by cutaneous malignant melanoma. We treated 369 patients (pts) suffering from malignant melanoma; they were submitted to surgical treatment related to the stage of disease; 196 (53.1%) of these patients had undergone systemic or locoregional chemotherapy; 41 pts (11.1%) had systemic immunotherapy with α -interferon. The mean follow-up was 39.7 months, median 30 months. Among all patients, 27 (7.3%) had a second primary neoplasm, diagnosed either previously (16 pts, 59.3%) or after (11 pts, 40.7%) melanoma diagnosis. For the entire group, there were five pts with breast cancer, four with head and neck cancer (1 tongue, 1 larynx, 2 thyroid), five with gynecologic tumours (3 with uterine and 2 with ovarian cancer), three with skin tumors (2 basal cells tumour and 1 further melanoma), two myeloproliferative tumours (1 Hodgkin lymphoma and 1 thrombocytosis), one with soft tissue sarcoma, one with lung cancer, four with gastrointestinal cancers (2 colorectal and 2 gastric cancer), two with urinary tract (1 kidney and 1 bladder cancer). The differential analysis of gender and age showed a trend for increasing incidence of the second cancer in females than males ($P = 0.23$, ns) and found that risk for the second tumour was higher in older ages ($P = 0.02$). Site, Breslow thickness, and therapy of primary melanoma were not predictive for a second cancer. Moreover, we found that breast and uterine cancer (hormone related cancer) was common in the group of neoplasms preceding melanoma. The incidence of second primary warrants a more careful follow-up in melanoma patients and their relatives.

220a

POSTER

IMPLICATION OF THE GLUTATHIONE ON B16 MELANOMA CELLS SENSITIVITY TO CYCLOPHOSPHAMIDE

P. Bilbao, T. Palomares, A. Alonso-Varona, A. Alvarez, J.C. Martin, J.T. Negueruela

Fac. de Medicina y Odontologia, Universidad del Pais Vasco/E.H.U. Leioa, Viscaya, Spain

Depletion of glutathione (GSH) has been proposed as a useful antitumour approach, increasing cellular sensitivity to other anticancer. GSH is a ubiquitous tripeptide thiol that has a critical role in protection of cells against the cytotoxic effects of a wide variety of drugs, such as activated cyclophosphamide (CY). It has been demonstrated that GSH can protect against the DNA cross-linking effect of this bifunctional alkylating agent, with consequent depletion of intracellular GSH levels. The depletion of GSH content following exposure to activated CY has been attributable to intracellularly released acrolein. Recently, we have shown in studies *in vivo*, that B16F10 melanoma cells are sensitive to CY treatment. Thus, high-dose CY therapy (300 mg/kg) significantly ($P < 0.001$) decreased the number and growth rate of B16 melanoma liver metastases, reducing the hepatic volume infiltrated by metastatic tissue and, therefore, increasing significantly ($P < 0.001$) the survival time of tumor-bearing treated mice in comparison to the control group. We observed that in the set of mice treated with CY the metastases became amelanotic whereas in the control group remain strongly pigmented. Because GSH is also involved in cell proliferation and in the melanin synthesis, in the present study we assessed, *in vitro*, the effect of acrolein on GSH levels of B16F10 melanoma cells. We observed that acrolein (10 μ M) significantly ($P < 0.005$) decreases the GSH levels and cell proliferation of these tumour cells. It is concluded that B16 melanoma cells are sensitive to CY therapy, decreasing the proliferation and melanogenesis of these tumour cells, and that depletion of intracellular GSH levels could be one of the possible mechanisms implicated (supported by UPV/EHU grant number 075.327 E117/94.)

220b

POSTER

INTRAVENOUS HIGH DOSE THYMOPENTIN IN METASTATIC MELANOMA PATIENTS: EVALUATION OF TOXICITY AND CLINICAL EFFICACY

N. Cascinelli, L. Mascheroni, F. Belli, M. T. Baldini, C. Clemente

National Cancer Institute of Milan, 20133 Milan, Italy

The study concerns a group of eight cases, firstly treated with 3 different modalities of dosing: Group A: 3 patients were treated with systemic Thymopentin (TP5) 1 gr/three times a week i.v. for 5 weeks; Group B: 3 patients received systemic TP5 1 gr/daily i.v. for 5 weeks; Group C: 2 patients had systemic TP5 2 gr/daily i.v. for 5 weeks. The clinical evaluation criteria included an immediate control at the end of dosing and a second check four weeks after ending therapy. The therapy was well tolerated by all the patients and no impact was produced on the daily activities or quality of life of treated cases. As far as concerns cutaneous metastases we obtained four Partial Responses and four Stable Disease. The duration of response ranged from 1 to 8 months (mean 4). Actually 6 patients are alive with disease and 2 patients died of disease.

Clinical and pathological data are indicating that i.v. high dose TP5 is an agent able to produce consistent biological and immunological effects in advanced melanoma patients, especially if cutaneous or subcutaneous metastases are considered.

221

POSTER

ACTIVE SPECIFIC IMMUNOTHERAPY (ASI) IN PATIENTS WITH METASTATIC MELANOMA (MM)

A.M.E. Claessen, A. Stam, H. Gall, R.J. Schepers, C.J.L.M. Meijer, J.B. Vermorken

Free University Hospital, Amsterdam, The Netherlands

Background: ASI has some promise in the treatment of patients (pts) with MM. Several clinical studies have demonstrated both humoral and cellular responses against melanoma antigens *in vitro* and an influx of tumor infiltrating lymphocytes in regressing metastatic lesions in MM pts. In general, vaccination with whole cell vaccines, either autologous or allogenic results in generation of melanoma specific delayed type hypersensitivity (DTH) reactivity *in vivo*.

Objectives: The purpose of our study was to reach maximal DTH response in individual MM pts and to evaluate whether the magnitude of these responses correlated with (progression-free) survival.

Methods: 44 MM pts were treated with autologous cell vaccines (2-16x, the first 2 admixed with BCG). Twenty-two pts had no evidence of disease after metastectomy (NED group), neither clinically nor pathologically. The other 22 pts (ED group) had either incomplete resection of MM (n = 9) or still clinical evidence of MM (n = 13). Vaccines were prepared from material obtained after surgery according to a standardized procedure.

Results: The majority of pts in the ED-group (median survival 7 months) did not show an important DTH response. Peripheral blood lymphocytes (PBLs) showed strongly decreased responses to mitogens and PPD, which did not change after vaccination. In contrast, the majority of pts in the NED group (median survival 16+ months) showed a high DTH response and DTH reactivity correlated with survival. PBL responsiveness to PPD was strongly enhanced after vaccination.

Conclusion: In particular, in NED MM pts improvement of vaccine preparation by maneuvers, which enhance DTH response should be further explored.

222

POSTER

INDUCTION OF SPECIFIC T-CELL RESPONSES *IN VITRO* AND *IN VIVO* WITH MELANOMA ASSOCIATED PEPTIDES

E. Jäger, M. Ringhoffer, M. Keyser, M. Arand, A. Knuth

II. Med. Klinik, Krankenhaus Nordwest, 60488 Frankfurt, Germany

Specific cytotoxic T-lymphocyte (CTL) activity against autologous melanoma cells is often generated by mixed tumor lymphocyte cultures (MLTC) *in vitro*. Targets for CTL responses are peptides of 9-10 aminoacids presented by MHC class I molecules. From HLA-A2+ melanoma systems extensively studied in our laboratory several antigenic peptides were recently characterized by molecular cloning and surface stripping of HLA class I bound peptides. All antigens identified are differentiation antigens of the melanocyte lineage (tyrosinase, gp100, Melan A). Their potential role for tumor rejection is currently unknown. To evaluate the toxicity and immunologic effects of intradermal injection of these peptides, a pilot study was conducted. Three patients (HLA A2+) with metastatic melanoma, who failed on conventional treatment protocols, were injected weekly with 100 μ g of peptides derived from Melan A (4 variants), tyrosinase (3 variants), gp100